Key result
This review discusses the pharmacology, toxicities, and clinical trial evidence regarding the use of intravenous hydroxyethyl starch (HES) for fluid resuscitation in critically ill and surgical patients.
Why the study?
Does hydroxyethyl starch (HES) compared to crystalloids affect mortality and renal outcomes in critically ill and surgical patients?
Does hydroxyethyl starch (HES) compared to crystalloids affect mortality and renal outcomes in critically ill and surgical patients?
The safety and efficacy of hydroxyethyl starch solutions appear highly context-dependent, with clear harms in septic ICU patients but debated risks in intraoperative settings.
Answers are grounded in this paper and cite their sources.
HES should be avoided in septic ICU patients; leaves open its perioperative safety profile.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Raghunathan et al. (2014) conducted a review in Hypovolemia and critical illness. Intravenous Hydroxyethyl Starch (HES) vs. Crystalloids or other fluids was evaluated. This review discusses the pharmacology, toxicities, and clinical trial evidence regarding the use of intravenous hydroxyethyl starch (HES) for fluid resuscitation in critically ill and surgical patients.
Synapse has enriched 10 related papers. Consider them for comparative context: